Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance

Condition(s) studied

Investigational drug(s) / intervention(s)

multiparametric MRI Diagnostics: Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found

Study summary

To investigate whether multiparametric MRI (mp-MRI) in patients with low-risk prostate cancer can improve the selection of patients suitable for Active Surveillance and have a relevance in the ongoing monitoring

Eligibility

Primary outcome measure(s)

• Changes in treatment from active surveillance (observation) to active treatment based on mp-MRI results. — 12 months
  Patients enrolled in active surveillance will progress to active treatment if mp-MRI show previously undetected suspicious areas of significant disease. Significant cancer (measured by Gleason score and cancer core involvement on biopsies) will be confirmed by repeat biopsies of the suspicious areas. The decision to progress to active treatment is based on decision from the treating urologist.

Trial sites (1)

More Herlev Hospital trials in Denmark

Other trials for the same condition